Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., executed a series of transactions on June 9, 2026.
• These transactions involved the exercise of 9,500 stock options at an exercise price of $146.03 per share.
• Following the option exercise, 9,500 shares of common stock were sold at a weighted average price of $544.6909.
• The sales were conducted under a 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026.
• Rothblatt's beneficial ownership of common stock following these transactions is 40,513 shares directly held, with additional shares held indirectly through a spouse, trusts, and a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the transactions are executed under a pre-arranged 10b5-1 plan, the significant sale of shares by a key executive warrants attention, though it is a planned event.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading.
• The plan allows for systematic selling of shares, potentially indicating a disciplined approach to managing personal holdings.
• The exercise of options at $146.03 and sale at an average price of $544.6909 indicates a significant gain on the exercised options.

Negatives

• A substantial number of shares were sold by a key executive, which could be perceived negatively by the market, despite being executed under a pre-arranged plan.
• The weighted average sale price across multiple transactions ranged from $544.15 to $552.95, indicating a significant volume of shares being sold.

Risks

• The ongoing nature of the 10b5-1 plan means further sales of common stock by the reporting person may occur.
• Market perception of significant insider selling, even under a plan, could negatively impact the stock price.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever comes first. This implies potential for further stock sales by the reporting person within this timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple sales transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology and pharmaceutical sectors, where executives often hold significant equity. The use of 10b5-1 plans is a standard practice for managing such holdings and mitigating insider trading concerns.

Stakeholder Impact

• Shareholders: May perceive the sale of shares by the CEO as a negative signal, despite the 10b5-1 plan, potentially impacting stock price. However, the plan itself is a governance mechanism to manage such sales.
• Employees: The stock price performance, influenced by insider transactions, can affect employee stock options and morale.
• Management: The CEO is managing personal equity holdings in a structured manner, adhering to regulatory guidelines.

Next Steps

• Continued execution of the 10b5-1 trading plan until its termination date (December 31, 2026) or completion of option exercise.
• Potential for further Form 4 filings detailing subsequent transactions under the plan.

Key Dates

Recommendation

The filing details planned stock sales by a key executive under a 10b5-1 plan. While significant, the pre-arranged nature mitigates immediate negative implications. The recommendation is to hold, pending further operational updates or market developments, as this filing primarily reflects personal financial planning rather than a change in company fundamentals.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, 10b5-1 Plan, Stock Options, Common Stock, Beneficial Ownership, Martine Rothblatt, SEC Filing